Prof. Dr. Stefan Lichtenthaler



Academic Career and Research Areas

Professor Lichtenthaler (b. 1968) conducts research on the molecular basis of neurodegenerative diseases such as Alzheimer’s disease. The goal is to gain a better understanding of these common forms of dementia, to develop new diagnostic and therapeutic approaches and to be able to better predict the possible side effects of medication. This research is carried out using biochemical and proteomic methods such as quantitative mass spectrometry.

Professor Lichtenthaler studied chemistry at the Universities of Karlsruhe, Montpellier (France) and Heidelberg. He earned his doctoral degree at ZMBH, Heidelberg University’s Center for Molecular Biology. After working as a postdoctoral researcher at Harvard University (USA) he led a junior research group at LMU Munich where he also acquired his postdoctoral teaching qualification (habilitation) for his work in the field of biochemistry. In 2009 he was appointed head of department at DZNE, the newly established German Center for Neurodegenerative Diseases. Since 2012 he has been full professor of proteomics at TUM and DZNE.


  • Alzheimer Research Award of the Hans and Ilse Breuer Foundation (2014)
  • Emmy-Noether grant recipient (1999-2001)
  • Dr. Sophie Bernthsen Prize recipient (1994)

Tüshaus J, Müller SA, Kataka ES, Zaucha J, Sebastian Monasor L, Su M, Güner G, Jocher G, Tahirovic S, Frishman D, Simons M, Lichtenthaler SF: “An optimized quantitative proteomics method establishes the cell type-resolved mouse brain secretome”. EMBO J. 2020; e105693.


Pigoni M, Hsia HE, Hartmann J, Rudan Njavro J, Shmueli MD, Müller SA, Güner G, Tüshaus J, Kuhn PH, Kumar R, Gao P, Tran ML, Ramazanov B, Blank B, Hipgrave Ederveen AL, Von Blume J, Mulle C, Gunnersen JM, Wuhrer M, Rammes G, Busche MA, Koeglsperger T, Lichtenthaler SF: “Seizure protein 6 controls glycosylation and trafficking of kainate receptor subunits GluK2 and GluK3”. EMBO J. 2020; 39, e103457.


Lichtenthaler SF, Güner G: "Pathology-linked protease caught in action". Science. 2019; 363 (6428), 690-691.


Brummer T, Müller SA, Pan-Montojo F, Fumiaki Y, Fellgiebel A, Tomita T, Endres K, Lichtenthaler SF: "NrCAM is a marker for substrate-selective activation of ADAM10 in Alzheimer's disease". EMBO Molecular Medecine. 2019; e9695.


Lichtenthaler SF, Lemberg M, Fluhrer R: "Proteolytic ectodomain shedding of membrane proteins in mammals - hardware, concepts and recent developments". The EMBO Journal. 2018; 37, e99456.